Literature DB >> 36183286

Correlation between clinical phenotype and electromyographic parameters in amyotrophic lateral sclerosis.

Eleonora Colombo1, Alberto Doretti1, Francesco Scheveger1,2, Alessio Maranzano1,2, Giulia Pata1, Delia Gagliardi3, Megi Meneri3,4, Stefano Messina1, Federico Verde1,4, Claudia Morelli1, Stefania Corti3,4, Luca Maderna1, Vincenzo Silani1,4, Nicola Ticozzi5,6.   

Abstract

INTRODUCTION: Even if electromyography (EMG) is routinely used to confirm the diagnosis of amyotrophic lateral sclerosis (ALS), few studies have analysed the correlation between electrophysiological parameters and clinical characteristics of ALS. We assessed if the quantification of active denervation (AD) and chronic denervation (CD) provides clinicians with information about phenotype, disease progression and survival in ALS patients.
METHODS: We studied a cohort of 689 ALS patients recording the following parameters: age and site of onset, survival, MRC scale for muscle strength evaluation, burden of upper and lower motor signs as measured with specific scales (PUMNS and LMNS, respectively), ALSFRS-R, progression rate (ΔFS), MITOS and King's Staging systems (KSS). We performed EMG on 11 muscles, and calculated semiquantitative AD and CD scores for each limb, as well as for the bulbar and spinal regions.
RESULTS: We found a positive correlation between AD and CD scores with LMNS (respectively p = 4.4 × 10-37 and p = 2.8 × 10-45) and a negative correlation with MRC (respectively p = 4.5 × 10-35 and p = 3.0 × 10-35). Furthermore, patients with higher spinal AD and CD scores had significantly lower ALSFRS-R scores, and higher KSS and MITOS stages. Conversely, only AD was associated to higher ΔFS (p = 1.0 × 10-6) and shorter survival (p = 1.1 × 10-5).
CONCLUSION: Our results confirmed that EMG examination represents not only a diagnostic instrument, but also a prognostic tool. In this context, AD seems to be a reliable predictor of disease's progression and survival while CD better describes functional disability.
© 2022. The Author(s).

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Clinical neurophysiology; Electromyography; Motor neuron disease

Year:  2022        PMID: 36183286     DOI: 10.1007/s00415-022-11404-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   6.682


  9 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  Diagnostic criteria for amyotrophic lateral sclerosis: A multicentre study of inter-rater variation and sensitivity.

Authors:  B Johnsen; K Pugdahl; A Fuglsang-Frederiksen; K Kollewe; L Paracka; R Dengler; J P Camdessanché; W Nix; R Liguori; I Schofield; L Maderna; D Czell; C Neuwirth; M Weber; V E Drory; A Abraham; M Swash; M de Carvalho
Journal:  Clin Neurophysiol       Date:  2018-12-09       Impact factor: 3.708

3.  Reliable and efficient scale to assess upper motor neuron disease burden in amyotrophic lateral sclerosis.

Authors:  Colin Quinn; Christyn Edmundson; Nabila Dahodwala; Lauren Elman
Journal:  Muscle Nerve       Date:  2019-12-20       Impact factor: 3.217

4.  A proposal for new diagnostic criteria for ALS.

Authors:  Jeremy M Shefner; Ammar Al-Chalabi; Mark R Baker; Li-Ying Cui; Mamede de Carvalho; Andrew Eisen; Julian Grosskreutz; Orla Hardiman; Robert Henderson; Jose Manuel Matamala; Hiroshi Mitsumoto; Walter Paulus; Neil Simon; Michael Swash; Kevin Talbot; Martin R Turner; Yoshikazu Ugawa; Leonard H van den Berg; Renato Verdugo; Steven Vucic; Ryuji Kaji; David Burke; Matthew C Kiernan
Journal:  Clin Neurophysiol       Date:  2020-04-19       Impact factor: 3.708

5.  Lower motor neuron involvement examined by quantitative electromyography in amyotrophic lateral sclerosis.

Authors:  Christian Krarup
Journal:  Clin Neurophysiol       Date:  2010-07-24       Impact factor: 3.708

Review 6.  Electrodiagnostic criteria for diagnosis of ALS.

Authors:  Mamede de Carvalho; Reinhard Dengler; Andrew Eisen; John D England; Ryuji Kaji; Jun Kimura; Kerry Mills; Hiroshi Mitsumoto; Hiroyuki Nodera; Jeremy Shefner; Michael Swash
Journal:  Clin Neurophysiol       Date:  2007-12-27       Impact factor: 3.708

7.  Sensitivity of electrophysiological tests for upper and lower motor neuron dysfunction in ALS: a six-month longitudinal study.

Authors:  Mamede de Carvalho; Michael Swash
Journal:  Muscle Nerve       Date:  2010-02       Impact factor: 3.217

Review 8.  Neurophysiological biomarkers in amyotrophic lateral sclerosis.

Authors:  Steve Vucic; Seward B Rutkove
Journal:  Curr Opin Neurol       Date:  2018-10       Impact factor: 5.710

9.  Targeted assessment of lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis.

Authors:  Matthew S Devine; Emma Ballard; Peter O'Rourke; Matthew C Kiernan; Pamela A Mccombe; Robert D Henderson
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2015-12-24       Impact factor: 4.092

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.